Sign in Subscribe
Prostate cancer

Accuray Incorporated's CyberKnife System Demonstrates Benefits in Prostate Cancer Treatment

Strategic Insights

— 1 min read

Accuray Incorporated's (NASDAQ: ARAY) CyberKnife System has shown to be an effective treatment option for prostate cancer at multiple stages of the disease, according to new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting. The studies indicate that the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body radiation therapy (SBRT). The data also suggest that the CyberKnife System is a safe and effective alternative to conventional treatments for localized prostate cancer.

Key Takeaways:

  • The CyberKnife System's accuracy and precision enable treatment of high-risk prostate cancer with stereotactic body radiation therapy (SBRT).
  • The system is also effective in treating recurrent prostate cancer following prostatectomy with minimal toxicity.
  • A retrospective analysis of 262 men with high-risk prostate cancer found that treatment with the CyberKnife System resulted in favorable outcomes and low rates of acute and late urogenital (UG) and gastrointestinal (GI) toxicities.
  • A prospective study of 51 patients with macroscopic prostate bed recurrence after prostatectomy found that the CyberKnife System provided an effective and convenient treatment option with mild toxicity.
  • Accuray Incorporated hosted a symposium at ESTRO attended by 350 healthcare professionals, featuring global thought leaders discussing advancements in genitourinary radiotherapy.
  • Suzanne Winter, president and CEO of Accuray Incorporated, stated that the company is grateful to the clinicians who continue to evaluate its technologies and advance personalized and precise care of patients.

Statistics:

  • 262 men were included in the retrospective analysis of high-risk prostate cancer patients treated with the CyberKnife System.
  • The median follow-up of the retrospective analysis was 39 months.
  • 51 patients were included in the prospective study of macroscopic prostate bed recurrence after prostatectomy treated with the CyberKnife System.
  • The median follow-up of the prospective study was 16 months.
  • The CyberKnife System delivers treatment in five sessions.

Sources:

  • Accuray Incorporated. News Release: Accuray Presents New Data at ESTRO Meeting Highlighting CyberKnife System's Benefits in Prostate Cancer Treatment. 2025.
  • European Society for Radiotherapy and Oncology. ESTRO Meeting 2025.

Read more